Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Atypical Lymphoproliferative Diseases.

Timothy Greiner, James O. Armitage, Thomas G. Gross

    Hematology. American Society of Hematology. Education Program
    |November 10, 2001
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Proteome landscape of B-cell malignancies identifies mantle cell lymphoma protein signature.

    bioRxiv : the preprint server for biology·2026
    Same author

    Cooperative role of distinctive TP53 and PTEN combined loss in the peripheral T cell lymphoma-GATA3 molecular subgroup.

    Science advances·2025
    Same author

    Mutation profiling in differential diagnosis between TdT-positive high-grade/large B-cell lymphoma and B-lymphoblastic leukaemia/lymphoma.

    The Journal of pathology·2025
    Same author

    Anaplastic large cell lymphoma presenting as a mass in the uterine cervix: a case report.

    Journal of hematopathology·2024
    Same author

    Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma.

    Blood·2022
    Same author

    Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma.

    Haematologica·2021

    This review covers rare lymphoid disorders, detailing their pathology, diagnosis, and treatment. It highlights challenges in differentiating reactive from malignant conditions and discusses management strategies for Castleman

    Area of Science:

    • Hematology
    • Oncology
    • Immunology

    Background:

    • Uncommon lymphoid proliferations present diagnostic and therapeutic challenges due to overlapping features of reactive and malignant conditions.
    • These disorders include Castleman's disease, angioimmunoblastic lymphadenopathy, autoimmune-related lymphadenopathy, post-transplant lymphoproliferative disorders, and X-linked lymphoproliferative disorder.
    • Associations with Epstein-Barr virus (EBV) and human herpesvirus-8 (HHV-8) are significant in some of these conditions.

    Purpose of the Study:

    • To review the clinical presentation, pathology, and therapy of several uncommon lymphoid proliferations.
    • To provide insights into molecular diagnostics and principles for accurate evaluation.
    • To discuss practical management approaches for specific disorders like Castleman's disease and EBV-associated lymphoproliferative disorders.

    Related Experiment Videos

    Main Methods:

    • Review of literature on the pathology of atypical lymphoid disorders.
    • Discussion of diagnostic assays and evaluation principles.
    • Presentation of therapeutic options, including surgical excision, corticosteroids, chemotherapy, anti-interleukin-6 therapy, and bone marrow transplantation.
    • Update on molecular discoveries and preliminary trial results for specific conditions.

    Main Results:

    • Detailed pathology of various atypical lymphoid disorders is described.
    • Management strategies for Castleman's disease emphasize diagnosis confirmation, staging, and diverse therapeutic options.
    • Treatment of EBV-associated lymphoproliferative disorders in immunocompromised patients is reviewed, including updates on X-linked lymphoproliferative disorder and preliminary trial data.

    Conclusions:

    • Accurate diagnosis and staging are crucial for effective management of uncommon lymphoid proliferations.
    • A range of therapeutic strategies, from conventional treatments to novel approaches, are available and should be tailored to the specific disorder.
    • Ongoing research into molecular mechanisms and clinical trials continues to refine treatment protocols for these rare conditions.